Topcon Healthcare, Inc.
$985.2K 688 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
InspireMD Ltd
InspireMD Ltd reported $983,444.00 across General Payments, Research, and Ownership to 64 physicians and teaching hospitals across 97 transactions.
- $983.4K Above-median payer
- All-tracks total
- 97 Below-median volume
- Transactions
- 64 Below-median reach
- Recipients
- −$55.1K
- General Payments vs PY2023
InspireMD Ltd reported $983,444.00 across all CMS Open Payments tracks (General + Research + Ownership) to 64 physicians and teaching hospitals in Program Year 2024 - ranking #623 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,023.00, averaging $15.4K per recipient.
How InspireMD Ltd's $983.4K all-tracks total breaks down
InspireMD Ltd's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
19/100
Transaction volume
F
11/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer inspiremd-ltd InspireMD Ltd
$983.4K · #623/1,925 · 0.0% industry · PY2024
- TOT $983.4K
- RANK #623
- SHARE 0.0%
- TXN 97
- RCP 64
- CAT 1
- GEN $11.0K
- ΔGEN −$55.1K
- TOP1 6.1%
- PY 2024
Volume peers
Nearest volume peer: Topcon Healthcare, Inc. ($985.2K)
InspireMD Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
InspireMD Ltd's CMS-reported General Payments decreased by $55.1K (−83.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INSPIREMD LTDPY2023: INSPIREMD LTDPY2024: InspireMD Ltd. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $66,092.00
- PY2024
- $11,023.00
What the Data Shows for InspireMD Ltd
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For InspireMD Ltd, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 1 general-payment categories charted below, "Food and Beverage" is the largest at $11.0K across 64 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads InspireMD Ltd's 1-category general-payment breakdown at $11.0K, 100.0% of the reported total.
How InspireMD Ltd divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $11.0K | 64 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,738.00 (24.8%) of $11,023.00 in this company's General Payments records across 64 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for InspireMD Ltd
The five named recipients with the highest reported General Payments from this company
- 1
Sean Lyden
$671.00 across 1 reported transactions
- 2
Erin Murphy
$623.00 across 1 reported transactions
- 3
Anish Thomas
$515.00 across 1 reported transactions
- 4
Eric Secemsky
$473.00 across 1 reported transactions
- 5
John Bacharach
$456.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
InspireMD Ltd ranks #623 of 1,925 by total payments (top 32% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,458 of 1,838 by HHI (bottom 21% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Garrison Dental Solutions : $162.0K total payments, HHI 308
- Ossio Inc : $357.9K total payments, HHI 307
- Sanara MedTech Inc. : $748.7K total payments, HHI 306
- Merz North America, Inc. : $3.5M total payments, HHI 306
- Silk Road Medical, Inc. : $2.8M total payments, HHI 303
- Balt USA, LLC : $457.3K total payments, HHI 303
- InspireMD Ltd (this company) : $11.0K total payments, HHI 302
- Synthes USA Products LLC : $235.8K total payments, HHI 302
- Paratek Pharmaceuticals, Inc. : $1.2M total payments, HHI 302
- Melinta Therapeutics, LLC : $573.7K total payments, HHI 300
- Avanos Medical : $867.2K total payments, HHI 298
- Atland Pharmaceuticals, LLC : $7.0K total payments, HHI 296
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as InspireMD Ltd's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about InspireMD Ltd.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with InspireMD Ltd.
Showing 6 of 1,924 companies with CMS-reported payment data.
pharmaand GmbH
$976.9K 57 recipients
Compare payment profiles
Melinta Therapeutics, LLC
$976.6K 4,777 recipients
Compare payment profiles
US Endoscopy
$971.8K 103 recipients
Compare payment profiles
Ortho Dermatologics, a division of Bausch Health US, LLC
$999.3K 13,977 recipients
Compare payment profiles
Bristol Myers Squibb Company
$1.0M 109 recipients
Compare payment profiles
Put this to use
InspireMD Ltd ranks #623 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where InspireMD Ltd sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just InspireMD Ltd. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.